Sino Biopharmaceutical Statistics

Total Valuation

Sino Biopharmaceutical has a market cap or net worth of HKD 69.00 billion. The enterprise value is 75.20 billion.

Market Cap	69.00B
Enterprise Value	75.20B

Important Dates

The next estimated earnings date is Friday, November 15, 2024.

Earnings Date	Nov 15, 2024
Ex-Dividend Date	Sep 10, 2024

Share Statistics

Sino Biopharmaceutical has 18.21 billion shares outstanding. The number of shares has decreased by -2.25% in one year.

Shares Outstanding	18.21B
Shares Change (YoY)	-2.25%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	49.69%
Owned by Institutions (%)	17.32%
Float	9.16B

Valuation Ratios

The trailing PE ratio is 30.38 and the forward PE ratio is 19.91. Sino Biopharmaceutical's PEG ratio is 1.08.

PE Ratio	30.38
Forward PE	19.91
PS Ratio	2.34
PB Ratio	1.96
P/FCF Ratio	11.16
PEG Ratio	1.08

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.01, with an EV/FCF ratio of 12.17.

EV / Earnings	17.11
EV / Sales	2.52
EV / EBITDA	11.01
EV / EBIT	12.79
EV / FCF	12.17

Financial Position

The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.23.

Current Ratio	1.15
Quick Ratio	0.94
Debt / Equity	0.23
Debt / EBITDA	1.43
Debt / FCF	1.68
Interest Coverage	16.51

Financial Efficiency

Return on equity (ROE) is 12.87% and return on invested capital (ROIC) is 7.35%.

Return on Equity (ROE)	12.87%
Return on Assets (ROA)	5.54%
Return on Capital (ROIC)	7.35%
Revenue Per Employee	1.22M
Profits Per Employee	179,852
Employee Count	25,806
Asset Turnover	0.42
Inventory Turnover	2.72

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +39.27% in the last 52 weeks. The beta is 0.72, so Sino Biopharmaceutical's price volatility has been lower than the market average.

Beta (5Y)	0.72
52-Week Price Change	+39.27%
50-Day Moving Average	3.26
200-Day Moving Average	3.01
Relative Strength Index (RSI)	59.69
Average Volume (20 Days)	88,648,962

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Sino Biopharmaceutical had revenue of HKD 29.86 billion and earned 4.40 billion in profits. Earnings per share was 0.24.

Revenue	29.86B
Gross Profit	24.24B
Operating Income	6.31B
Pretax Income	6.41B
Net Income	4.40B
EBITDA	7.20B
EBIT	6.31B
Earnings Per Share (EPS)	0.24

Full Income Statement

Balance Sheet

The company has 14.16 billion in cash and 10.40 billion in debt, giving a net cash position of 3.76 billion or 0.21 per share.

Cash & Cash Equivalents	14.16B
Total Debt	10.40B
Net Cash	3.76B
Net Cash Per Share	0.21
Equity (Book Value)	45.26B
Book Value Per Share	1.94
Working Capital	3.52B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 6.96 billion and capital expenditures -775.15 million, giving a free cash flow of 6.18 billion.

Operating Cash Flow	6.96B
Capital Expenditures	-775.15M
Free Cash Flow	6.18B
FCF Per Share	0.34

Full Cash Flow Statement

Margins

Gross margin is 81.16%, with operating and profit margins of 21.12% and 14.72%.

Gross Margin	81.16%
Operating Margin	21.12%
Pretax Margin	21.48%
Profit Margin	14.72%
EBITDA Margin	24.11%
EBIT Margin	21.12%
FCF Margin	20.70%

Dividends & Yields

This stock pays an annual dividend of 0.06, which amounts to a dividend yield of 1.58%.

Dividend Per Share	0.06
Dividend Yield	1.58%
Dividend Growth (YoY)	-25.00%
Years of Dividend Growth	n/a
Payout Ratio	15.47%
Buyback Yield	2.25%
Shareholder Yield	3.84%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

The last stock split was on July 20, 2020. It was a forward split with a ratio of 1.5.

Last Split Date	Jul 20, 2020
Split Type	Forward
Split Ratio	1.5

Scores

Sino Biopharmaceutical has an Altman Z-Score of 2.71. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.71
Piotroski F-Score	n/a